ACRIX
Price
$27.65
Change
+$0.12 (+0.44%)
Updated
Jul 31 closing price
Net Assets
1.55B
HCYAX
Price
$18.50
Change
-$0.00 (-0.00%)
Updated
Jul 31 closing price
Net Assets
133.71M
Interact to see
Advertisement

ACRIX vs HCYAX

ACRIX vs HCYAX Comparison Chart in %
View a ticker or compare two or three
VS
ACRIX vs. HCYAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRIX is a Hold and HCYAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
ACRIX has more cash in the bank: 1.55B vs. HCYAX (134M). HCYAX pays higher dividends than ACRIX: HCYAX (3.88) vs ACRIX (0.68). ACRIX was incepted earlier than HCYAX: ACRIX (10 years) vs HCYAX (13 years). HCYAX (1.51) is less costly to investors than ACRIX (1.15). ACRIX is a more actively managed with annual turnover of: 172.00 vs. HCYAX (92.00). HCYAX has a lower initial minimum investment than ACRIX: HCYAX (2500) vs ACRIX (10000000). ACRIX annual gain was more profitable for investors over the last year : 9.58 vs. HCYAX (5.32). HCYAX return over 5 years is better than : 16.59 vs. ACRIX (10.24).
ACRIXHCYAXACRIX / HCYAX
Total Expense Ratio1.151.2989%
Annual Report Gross Expense Ratio1.151.5176%
Fund Existence10 years13 years-
Gain YTD9.7663.198305%
Front LoadN/AN/A-
Min. Initial Investment100000002500400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.55B134M1,157%
Annual Yield % from dividends0.683.8818%
Returns for 1 year9.585.32180%
Returns for 3 years25.3624.53103%
Returns for 5 years10.2416.5962%
Returns for 10 yearsN/A54.86-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASPYX39.140.43
+1.11%
Alger Spectra Y
OLGAX77.840.54
+0.70%
JPMorgan Large Cap Growth A
MENRX9.730.06
+0.62%
Madison Covered Call & Equity Income R6
EISDX36.680.07
+0.19%
Carillon ClariVest Intl Stock C
RYSEX17.78-0.07
-0.39%
Royce Small-Cap Special Equity Invmt